Partnership expansion AUM Biosciences has recently expanded its collaboration with Handok Inc. and CMG Pharmaceutical for the development and commercialization of CHC2014. This partnership opens doors for potential sales opportunities by leveraging their specific pan-TRK inhibitor in the global market.

Series A funding boost With significant funding of $27 million in the recent Series A round led by Everlife and SPRIM Global Investments, AUM Biosciences is well-positioned for growth. This financial backing provides a strong foundation for potential sales expansion and market penetration strategies.

Award recognition AUM Biosciences' recognition as the 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year by Frost & Sullivan showcases its industry leadership. Leveraging this prestige can enhance brand perception and credibility, facilitating sales conversations and partnerships with key stakeholders.

Precision oncology focus AUM Biosciences specializes in precision oncology therapeutics aimed at reversing cancer resistance. This unique approach addresses unmet medical needs, presenting a compelling value proposition to potential customers and partners in the biotechnology research sector.

Investor interest The continuous interest and investments from reputable firms like Everlife and SPRIM Health Group indicate confidence in AUM Biosciences' potential. Utilizing this endorsement can boost sales initiatives by showcasing trustworthiness and business viability to target investors and clients.